Here are 1-3 brief analogies to describe BlossomHill Therapeutics:

• BlossomHill Therapeutics is like AstraZeneca, but specifically for overcoming advanced drug resistance in lung cancer.
• BlossomHill Therapeutics is like Blueprint Medicines, but focused on creating 'resistance-proof' targeted therapies for various cancer types.

• BH-30643: An investigational OMNI-EGFR inhibitor designed to treat a broad spectrum of EGFR-mutant non-small cell lung cancer, including resistant mutations like C797S, with selectivity over wild-type EGFR.
• BH-30236: An investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated for the treatment of relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes.
• BH-501284: A preclinical-stage product candidate designed to selectively target and modulate activated KRAS, aiming for prolonged, potent, and selective inhibition across KRAS mutations.

BlossomHill Therapeutics (BLSM) is a clinical-stage biopharmaceutical company focused on the research and development of innovative small molecule medicines. Its product candidates (BH-30643, BH-30236, and BH-501284) are currently investigational and are undergoing clinical trials or are in preclinical stages.

As these product candidates have not yet received regulatory approval from authorities like the U.S. Food and Drug Administration (FDA) and are not commercialized, BlossomHill Therapeutics does not currently have major customers or generate revenue from product sales.

J. Jean Cui, Ph.D. Scientific Founder, President and CEO

J. Jean Cui, Ph.D., is the scientific founder, President, and CEO of BlossomHill Therapeutics. Dr. Cui was also the scientific founder and Chief Scientific Officer of Turning Point Therapeutics, Inc. Turning Point Therapeutics went public on NASDAQ in April 2019 and was subsequently acquired by Bristol-Myers Squibb in 2022 for $4.1 billion. Her prior experience includes roles as a senior principal scientist and associate research fellow at Pfizer and as a project leader and group leader at SUGEN, Inc. (a Pharmacia Corporation). She has significantly contributed to oncology drug discovery and development, leading the design and development of three FDA-approved medicines: repotrectinib (AUGTYRO®), crizotinib (XALKORI®), and lorlatinib (LORBRENA®).

Jason Keyes, MBA. Executive Vice President and Chief Financial Officer

Jason Keyes, MBA, serves as the Executive Vice President and Chief Financial Officer of BlossomHill Therapeutics. With nearly 25 years in the biotechnology industry, he previously held the CFO position at Equillium, Inc. for over seven years, and also served as Chief Financial Officer of Orexigen Therapeutics, Inc. His career includes various corporate finance and strategic planning roles at Amylin Pharmaceuticals, Inc., Amgen, Inc., and Baxter Healthcare Corporation.

Y. Peter Li, Ph.D., MBA. Cofounder and Executive Chairman

Y. Peter Li, Ph.D., MBA, is the Cofounder and Executive Chairman of BlossomHill Therapeutics. He co-founded the company with J. Jean Cui.

Geoff Oxnard, M.D. Executive Vice President and Chief Medical Officer

Geoff Oxnard, M.D., is the Executive Vice President and Chief Medical Officer of BlossomHill Therapeutics. He is a globally recognized clinical and translational cancer investigator, having spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School. His research has provided early clinical insights into EGFR inhibitors in advanced lung cancer, including the initial description of the EGFR C797S resistance mutation.

Vincent Liptak, J.D., Ph.D., MBA. Executive Vice President and General Counsel

Vincent Liptak, J.D., Ph.D., MBA, serves as the Executive Vice President and General Counsel for BlossomHill Therapeutics.

The primary risks to BlossomHill Therapeutics (BLSM) are inherently tied to its status as a clinical-stage biopharmaceutical company with its entire pipeline of investigational drug candidates. The most significant risks include:

1. Risk of Clinical Trial Failure and Inability to Obtain Regulatory Approval

   BlossomHill Therapeutics' future largely depends on the successful outcome of its clinical trials and the subsequent ability to obtain regulatory approvals for its investigational drug candidates. Their most advanced product candidate, BH-30643, is currently in a Phase 1/2 clinical trial, and the company plans to seek an end-of-Phase 1 meeting with the FDA regarding a potential accelerated approval pathway in Q4 2026. This reliance on an accelerated approval pathway introduces regulatory uncertainty, as such approvals are not guaranteed. Similarly, BH-30236 is in an earlier Phase 1 trial, and BH-501284 is still in preclinical development with an IND submission planned for Q1 2027. Failure at any stage of these clinical trials due to lack of efficacy, unacceptable safety profiles, or challenges in manufacturing, or the inability to secure necessary regulatory approvals, would severely impact the company's prospects.

2. Competition in the EGFR-mutant NSCLC Market

   BlossomHill's lead candidate, BH-30643, targets EGFR-mutant non-small cell lung cancer (NSCLC), a field where "commercially available drugs targeting EGFR subtypes" already exist. The company acknowledges "a fragmentation of care in EGFR-mutant NSCLC because no drug is effective across all EGFR mutations." While BH-30643 is designed to address a broad spectrum of EGFR mutations, including resistance mutations like C797S, the market is highly competitive. The company will need to demonstrate clear advantages in efficacy, safety, and broad applicability over existing and emerging therapies to achieve significant market penetration and overcome the challenges posed by an already fragmented treatment landscape.

3. Dependence on a Limited and Early-Stage Pipeline

   BlossomHill Therapeutics has a limited number of drug candidates in its pipeline, with only two in clinical development (BH-30643 and BH-30236) and one in preclinical stages (BH-501284). The company's most advanced candidate, BH-30643, is still in Phase 1/2. This high concentration of risk on a few early-stage assets means that the failure or significant delay of any one of these programs, particularly BH-30643, would have a disproportionately significant negative impact on the company's financial condition and future prospects.

BlossomHill Therapeutics' main product candidates target significant addressable markets:

• BH-30643 for Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC): The global EGFR-mutated lung cancer treatment market is projected to grow from approximately USD 16.1 billion in 2026 to USD 39.2 billion by 2036. In 2025, the EGFR NSCLC market size in the leading markets (the United States, the EU4 countries comprising Germany, France, Italy, and Spain, the United Kingdom, and Japan) was approximately USD 6,600 million. The global EGFR non-small cell lung cancer market size was valued at USD 9.34 billion in 2025 and is expected to reach USD 13.74 billion by 2030.

• BH-30236 for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS):

  • For Acute Myeloid Leukemia (AML), the global treatment market size was valued at USD 3.5 billion in 2024 and is projected to reach USD 6.3 billion by 2030. Another estimate places the global acute myeloid leukemia treatment market size at approximately USD 4.28 billion in 2026, with projections to reach around USD 10.64 billion by 2035. North America held the largest share of the global acute myeloid leukemia treatment market, accounting for 41% in 2025.

  • For Myelodysplastic Syndromes (MDS), the therapeutics market size in the leading markets (the United States, EU4, the United Kingdom, and Japan) was approximately USD 4,300 million in 2025. The myelodysplastic syndrome drugs market size was valued at USD 5.34 billion in 2024 and is projected to grow to USD 10.11 billion by 2035. North America accounted for approximately 48.0% of the global myelodysplastic syndromes drugs market in 2025. Higher-risk MDS patients constitute approximately 25-30% of all Myelodysplastic Syndrome patients.

• BH-501284 for pan-KRAS: The KRAS inhibitors market across the seven major markets was valued at approximately USD 526 million in 2025 and is projected to reach approximately USD 7.85 billion by 2034, with the United States expected to account for nearly 70% of the total. Another report estimates the global KRAS inhibitors market to be approximately USD 2.1 billion in 2024, with a projection to surpass USD 6.5 billion by 2030. KRAS mutations are found in approximately 85% of RAS-associated cancers, including about 90% of pancreatic cancers and 40% of colorectal cancers.

BlossomHill Therapeutics (BLSM) is expected to have several drivers of future revenue growth over the next 2-3 years, primarily centered around its lead product candidate, BH-30643, and its strategic development path:

1. Potential Accelerated Approval and Commercialization of BH-30643 for C797S-positive EGFR-mutant NSCLC: The company plans to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 regarding a potential accelerated approval pathway for BH-30643 in patients with advanced or metastatic C797S-positive EGFR-mutant non-small cell lung cancer (NSCLC). This population currently has no approved targeted therapy, representing a significant unmet medical need and a clear path to market entry and revenue generation within the next 2-3 years.
2. Expansion of BH-30643 Indications to a Broader Spectrum of EGFR Mutations: While initial approval may focus on C797S resistance, BH-30643 is designed to address a broad spectrum of EGFR mutations, including classical mutations, T790M, atypical mutations, and exon 20 insertion mutations. The early clinical data supports its potential against this broad spectrum, suggesting that subsequent label expansions beyond C797S could significantly broaden the addressable market and drive substantial revenue growth for the product.
3. Strategic Partnerships or Licensing Agreements for BH-30643: Given the advanced clinical stage of BH-30643, its potential for accelerated approval in an area of high unmet need, and its broad applicability across various EGFR mutations, BlossomHill Therapeutics may attract strategic partnerships or licensing agreements. Such collaborations could involve upfront payments, milestone payments, or co-commercialization arrangements, providing significant non-dilutive capital and a substantial revenue stream for the company within the forecast period.